Thyroid Gland Disorders is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Thyroid Gland Disorders have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Thyroid Gland Disorders compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Thyroid Gland Disorders overview
Thyroid gland disorders are conditions that affect the function of the thyroid, a butterfly-shaped gland in the front of the neck. The thyroid produces hormones that regulate metabolism, growth, development and body temperature. Some of the common thyroid disorders are hypothyroidism, goiter, hyperthyroidism, and thyroid cancer. Thyroid disorders can be diagnosed by blood tests that measure the levels of thyroid hormones and thyroid-stimulating hormone (TSH). Treatment depends on the type and severity of the disorder and may include medication, surgery, radioactive iodine, or hormone replacement therapy.
For a complete picture of PTSR and LoA scores for drugs in Thyroid Gland Disorders, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
